Want to see DRIO full AI Analyst Report?
DRIO Stock Chart & Stats
$7.39
-$0.32(-4.11%)
At close: 4:00 PM EDT
$7.39
-$0.32(-4.11%)
Day’s Range― - ―
52-Week Range$5.84 - $17.74
Previous Close$7.47
Volume8.71K
Average Volume (3M)28.00K
Market Cap
$70.95M
Enterprise Value$79.83
Total Cash (Recent Filing)$14.25M
Total Debt (Recent Filing)$32.41M
Price to Earnings (P/E)10.5
Beta0.20
Next Earnings
Nov 16, 2026EPS Estimate
-0.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.26
Shares Outstanding9,799,481
10 Day Avg. Volume38,495
30 Day Avg. Volume28,004
Financial Highlights & Ratios
PEG Ratio-1.49
Price to Book (P/B)8.32
Price to Sales (P/S)25.26
P/FCF Ratio-21.65
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.00Price Target Upside35.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.01
Revenue Forecast (FY)$23.03M
Bulls Say, Bears Say
Bulls Say
Margin Expansion And Cost DisciplineHigher gross margins and sustained expense reductions improve unit economics and operating leverage. If maintained as revenue scales, these changes can reduce the funding required to grow and support a more durable path toward breakeven.
Contracted ARR And Multi-condition Account GrowthThe contracted pipeline provides visibility into future recurring revenue, while multi-condition adoption can deepen customer relationships and increase revenue per account. Channel-led distribution and 180-plus signed accounts broaden the platform’s commercial reach.
AI, Data And Product ExpansionA large longitudinal dataset and broader condition coverage can strengthen personalization, engagement and retention. New programs also expand the addressable market and create opportunities to cross-sell additional services through existing organizational customers.
Bears Say
Sharp Revenue ContractionThe severe top-line decline indicates that commercial execution and revenue continuity remain major risks. Even with an improving pipeline, rebuilding the revenue base will require successful implementations, enrollment growth and sustained customer demand.
Persistent Cash Burn And Operating LossesContinued cash consumption limits financial flexibility and leaves the company dependent on its cash balance or external financing. Operating losses also show that margin improvements have not yet translated into self-funded growth or durable profitability.
Commercial Leadership TransitionA change in senior commercial leadership can disrupt customer relationships, sales execution and strategic continuity during a critical growth phase. The consulting arrangement preserves some expertise, but accountability and execution responsibility are being reconfigured.
DarioHealth News
DRIO FAQ
What was DarioHealth Corp’s price range in the past 12 months?
DarioHealth Corp lowest stock price was $5.84 and its highest was $17.74 in the past 12 months.
What is DarioHealth Corp’s market cap?
DarioHealth Corp’s market cap is $70.95M.
When is DarioHealth Corp’s upcoming earnings report date?
DarioHealth Corp’s upcoming earnings report date is Nov 16, 2026 which is in 70 days.
How were DarioHealth Corp’s earnings last quarter?
DarioHealth Corp released its earnings results on Aug 11, 2026. The company reported -$0.85 earnings per share for the quarter, beating the consensus estimate of -$1.215 by $0.365.
Is DarioHealth Corp overvalued?
According to Wall Street analysts DarioHealth Corp’s price is currently Undervalued.
Does DarioHealth Corp pay dividends?
DarioHealth Corp does not currently pay dividends.
What is DarioHealth Corp’s EPS estimate?
DarioHealth Corp’s EPS estimate is -0.95.
How many shares outstanding does DarioHealth Corp have?
DarioHealth Corp has 9,799,481 shares outstanding.
What happened to DarioHealth Corp’s price movement after its last earnings report?
DarioHealth Corp reported an EPS of -$0.85 in its last earnings report, beating expectations of -$1.215. Following the earnings report the stock price went up 0.131%.
Which hedge fund is a major shareholder of DarioHealth Corp?
Currently, no hedge funds are holding shares in DRIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DarioHealth Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (35.32% Upside)
$10.00 (35.32% Upside)
Blogger Sentiment
Neutral
DRIO Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.15%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.83%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
DarioHealth Corp
DarioHealth Corp. is a digital therapeutics enterprise operating across the United States, Canada, the European Union, Australia, and New Zealand. The company delivers a suite of digital health solutions, including its 'Dario' metabolic programs designed to address conditions like diabetes, hypertension, and weight management. They also offer 'Dario Musculoskeletal' for preventing and treating common MSK conditions, and 'Dario' behavioral health solutions to improve access to evidence-based care. Their offerings extend to general chronic condition management solutions and DarioEngage, a proprietary care management platform. In terms of hardware, DarioHealth provides smart glucose meters, Bluetooth-connected blood pressure cuffs, digital scales, biofeedback sensor devices, and disposables such as test strip cartridges and lancets for blood glucose monitoring systems. Furthermore, they offer comprehensive diabetes management programs that integrate lifestyle changes, healthy eating guidance, advanced tracking tools, and live coaching. Founded in 2011, the company was formerly known as LabStyle Innovations Corp. before officially changing its name to DarioHealth Corp. in July 2016. Its headquarters are located in New York, New York.
DRIO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized meaningful operational progress: stronger gross margins, disciplined expense reductions, improvement in net loss, a sizable ARR pipeline ($13.1M) that is predominantly multi-condition, a strengthened cash position (~$36.8M pro forma), and product/AI-driven commercialization (DarioIQ, GLP-1, Dario Women, Dario Sleep). The principal near-term concern is a modest decline in reported revenue due to strategic channel transitions and the multi-quarter lag between contract signings and recognized recurring revenue. Management framed these as temporary/timing issues while highlighting durable improvements in margin, efficiency, and the quality of future revenue. Overall, the positives around margin expansion, expense discipline, sales pipeline quality, AI/data advantages, and cash runway materially outweigh the near-term topline timing headwinds.View all DRIO earnings summariesDRIO Stock 12 Month Forecast
Average Price Target
$10.00
▲(35.32% Upside)
Technical Analysis
Ownership Overview
5.62% Insiders
1.20% Mutual Funds
6.23% Other Institutional Investors
86.07% Public Companies and
Individual Investors